O
ONCIN
vs
O
Oslo OBX
Over the past 12 months, ONCIN has underperformed Oslo OBX, delivering a return of -91% compared to the Oslo OBX's +16% growth.
Stocks Performance
ONCIN vs Oslo OBX
Performance Gap
ONCIN vs Oslo OBX
Performance By Year
ONCIN vs Oslo OBX
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Oncoinvent ASA
Glance View
Oncoinvent ASA engages in the development of cancer treatment products. The company is headquartered in Oslo, Oslo and currently employs 34 full-time employees. The company went IPO on 2024-12-13. The firm is engaged in the development of alpha-emitting radiotherapeutics that provide better treatment options to cancer patients. The firm offers Radspherin, which is alpha-emitting radioactive microsphere therapy designed for the treatment of metastatic cancers in body cavities. The product candidate is a suspension of inorganic microspheres labelled with an alpha-emitting radioisotope for local administration. More specifically it consists of with calcium carbonate micro particles labelled with the radioisotope Radium-224d. The therapeutic goal is to treat residual micro metastases remaining after surgery in intracavitary surfaces and liquid without subjecting deeper regions of organs and tissues to harmful radiation doses.